Table 3 from Initial-Care Medical and Prescription Costs for Incident Metastatic versus Nonmetastatic Colorectal Cancer

This is a Quantitative Study study.

October 20, 2025Open Access

View Full Paper

Ask AI

Bookmark

Share

Key Points

Patients with metastatic colorectal cancer face significantly higher out-of-pocket expenses compared to those with nonmetastatic disease.
The analysis reveals prescription costs for mCRC patients are notably greater, leading to increased financial strain.
Outpatient pharmacy charges exhibit a noticeable difference between metastatic and nonmetastatic colorectal cancer patients, highlighting disparities.
Understanding the costs associated with metastatic colorectal cancer may guide policy and financial support for affected patients.

Analysis shows prescription charges and out-of-pocket expenses differ in metastatic colorectal cancer patients, indicating financial burdens.

Outpatient pharmacy prescription charges and OOP expenses between patients with mCRC and non-mCRC(in $2023).

No takes yet. Share an insight, caveat, or question.

Nguyen et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share